complement therapeutics

News

Complement raises €72m for geographic atrophy gene therapy

UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing

News

AstraZeneca scores phase 3 win with novel complement drug da...

Prospects for AstraZeneca's oral Factor D inhibitor danicopan were looking poor after it failed a phase 2 trial in a rare kidney disease in 2020, but a new readout could reinvigorate the dr

News

Longer-term data raise prospects for Apellis' pegcetacoplan

Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from

News

Novartis' iptacopan hits the mark in rare kidney disease C3G

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated wi

News

Apellis reports mixed data with eye drug, but plans to file ...

Apellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major cause of blindness – with one hit and one miss in its phase 3 programme.

News